Mania switch induced by amantadine in bipolar disorder: report of three cases

Sodré, Leonardo de Almeida; Bücker, Joana; Zortéa, Karine; Sulzbach-Vianna, Miréia; Gama, Clarissa Severino

doi:10.1590/s1516-44462010000400029

Cited by 7 publications

(3 citation statements)

References 4 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, some case reports suggest that amantadine can be useful for the treatment of sexual dysfunction that is induced by serotonergic antidepressants 80,81. A case series with three patients suggested that high-dose amantadine induced a switch to mania in bipolar patients,82 a side effect that has also been reported for several antidepressant drugs.…”

Section: Resultsmentioning

confidence: 98%

Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials

Raupp-Barcaro

Vital

Galduróz

et al. 2018

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 98%

Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials

Raupp-Barcaro

Vital

Galduróz

et al. 2018

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…Treatment with amantadine for a short, two-week period of stabilizing improvement did not result in cycle acceleration, and discontinuation of the drug after such a period did not cause the recurrence of depressive symptoms. The reason for the short period of stabilization treatment with amantadine was to minimize the risk of manic switch reported in the Letter to the Editor by Sondré et al [ 45 ], in which amantadine was administered to 3 patients with BD-I. Although in the cases described in this report, patients received a high dose of 400 mg/day for 8 weeks, we thought that caution should be exercised in the duration of amantadine treatment after the improvement of depressive symptoms.…”

Section: Discussionmentioning

confidence: 99%

Possibility of a New Indication for Amantadine in the Treatment of Bipolar Depression—Case Series Study

Krzystanek

Pałasz

2020

Pharmaceuticals

View full text Add to dashboard Cite

Bipolar disorder is a chronic and remitting mental illness. Antidepressants are not effective in treating acute bipolar depression, and antipsychotic drugs used in the treatment of bipolar depression cause frequent side effects. This situation justifies the search for new drugs as well as the repurposing of drugs used in other indications. In an open and naturalistic serious case study, 4 patients diagnosed with bipolar I disorder, chronically treated with a mood stabilizer, in whom at least two antidepressants were ineffective in the depressive phase, were treated with amantadine. The woman received 100 mg/day and 3 men received the target dose of 200 mg/day. All patients treated with amantadine improved their depressive symptoms after 1 week of treatment. None of them experienced side effects or manic switch. To reduce the risk of a manic switch, the treatment with amantadine was discontinued 2 weeks after the improvement of depressive symptoms, and no recurrence of depressive symptoms was observed. Amantadine may be a further therapeutic option for the treatment of acute bipolar depression. The drug in this indication may act quickly and be well tolerated. Confirmation of the antidepressant efficacy of amantadine in this indication requires replication of the results and conducting clinical trials.

show abstract

“…Careful monitoring is required when amantadine is administered concurrently with central nervous system stimulants. A switch to mania has been described in vulnerable bipolar patients (Sodre, Bucker, Zortea, Sulzbach-Vianna, & Gama, 2010;Rego & Giller, 1989).…”

Section: Safety Datamentioning

confidence: 99%

Electroconvulsive therapy in adolescents with intellectual disability and severe self-injurious behavior and aggression: a retrospective study

Consoli

Cohen

Bodeau

et al. 2012

Eur Child Adolesc Psychiatry

View full text Add to dashboard Cite

Efficacious intervention for severe, treatment-refractory self-injurious behavior and aggression (SIB/AGG) in children and adolescents with intellectual disability and concomitant psychiatric disorders remains a complex and urgent issue. The aim of this study is to assess the efficacy of electroconvulsive therapy (ECT) on severe and treatment-resistant SIB/AGG in young people with intellectual disability and current psychiatric disorder. We reviewed the charts of all patients (N = 4) who received ECT in the context of SIB/AGG with resistance to behavioral interventions, milieu therapy and pharmacotherapy from 2007 to 2011. We scored the daily rate of SIB/AGG per patient for each hospital day. Inter rater reliability was good (intraclass correlations = 0.91). We used a mixed generalized linear model to assess whether the following explanatory variables (time, ECT) influenced the course of SIB/AGG over time, the dependant variable. The sample included two girls and two boys. The mean age at admission was 13.8 years old [range 12-14]. The patients had on average 19 ECT sessions [range 16-26] and one patient received maintenance ECT. There was no effect of time before and after ECT start. ECT was associated with a significant decrease in SIB/AGG scores (p < 0.001): mean aggression score post-ECT was half the pre-ECT value. ECT appears beneficial in severe, treatment-resistant SHBA in adolescents with intellectual disability.

show abstract

Mania switch induced by amantadine in bipolar disorder: report of three cases

Cited by 7 publications

References 4 publications

Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials

Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials

Possibility of a New Indication for Amantadine in the Treatment of Bipolar Depression—Case Series Study

Electroconvulsive therapy in adolescents with intellectual disability and severe self-injurious behavior and aggression: a retrospective study

Contact Info

Product

Resources

About